Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
60%(6 trials)

Phase Distribution

Ph phase_2
4
36%
Ph phase_3
3
27%
Ph phase_1
4
36%

Phase Distribution

4

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (36.4%)
Phase 24 (36.4%)
Phase 33 (27.3%)

Trials by Status

withdrawn19%
completed1091%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
completedphase_2

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01372410
completedphase_2

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

NCT00515502
completedphase_1

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

NCT00475436
completedphase_1

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects

NCT00976144
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01387230Phase 3

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Completed
NCT01372410Phase 2

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00515502Phase 2

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT00475436Phase 1

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Completed
NCT00976144Phase 1

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects

Completed
NCT01128634Phase 1

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Completed
NCT01521377Phase 1

QTc Study GSK573719+GW642444

Completed
NCT01316913Phase 3

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Completed
NCT01702363Phase 3

Long-term Safety Study for GSK573719 in Japanese

Completed
NCT00732472Phase 2

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Completed
NCT01653483Phase 2

Aura Adolescent PK Study GSK2829332

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11